FINWIRES · TerminalLIVE
FINWIRES

Surgery Partners Delivered Solid Q1 Beat Amid Stabilizing Portfolio, RBC Says

By

Surgery Partners (SGRY) delivered a solid Q1 beat, indicating a stabilizing portfolio, RBC Capital Markets said in a note emailed Wednesday.

The company reported a Q1 adjusted net loss of $0.03 per diluted share and $810.9 million in revenue. Analysts polled by FactSet expected loss of $0.12 per share and $797.7 million in revenue.

Surgery Partners' management said the three hospitals that weighed on its Q4 results are now performing in line with expectations as they continue to implement recovery plans, with new leadership, RBC noted.

In addition, the company is advancing its efforts to diversify outside of its core short-stay model, the brokerage said. Surgery Partners is looking to restructure ownership of a few larger surgical hospitals and is in advanced talks over an opportunity that could by announced by mid-2026, RBC added.

RBC reiterated its outperform rating and $20 price target on Surgery Partners.

Price: $13.96, Change: $-0.01, Percent Change: -0.07%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP